Singapore, Sep. 15, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the Best Biologics CMO Award for automation from IMAPAC, a leading consulting firm in the biopharmaceutical industry, at the Asia Pacific Biologics CMO Excellence Awards (APBCEA) ceremony. This marks the first time WuXi Biologics has received the automation related industry award.
The award honors WuXi Biologics’ achievements in driving efficiency, precision, and quality throughout the different stages of biologics research, development and manufacturing by incorporating automation technologies into its services. The company was one of the first biologics CMOs in Asia to adopt robotic aseptic filling lines and receive regulatory approval. It also implemented laboratory automation leading to superior process control and product consistency. With these advances, WuXi Biologics is able to offer faster, better and more economical solutions for global clients, achieving a higher bioreactor success rate while lowering labor costs.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “Being recognized this year with the Best Biologics CMO Award for automation and having received other consecutive awards from IMAPAC are great honors for WuXi Biologics. By leveraging innovative automation technologies, we will continue providing more efficient and cost-effective service solutions to enable our global partners for the benefit of patients worldwide.”
The Asia-Pacific CMO Excellence Awards seeks to give recognition to exceptional CMOs and CDMOs that facilitate biologics manufacturing excellence at enhanced speed, reduced cost, and superior quality from the biologics contract manufacturing space. Featuring top CMO/CDMO leaders in the industry, along with the latest advances in technologies and best practices in biologics R&D and manufacturing, the Asia Pacific Biologics CMO Excellence Awards 2023 applauds the extraordinary leaders and trend-setters of today, and inspires the innovators of tomorrow.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.